Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 5 | 2023 | 146 | 2.280 |
Why?
|
| Cisplatin | 2 | 2023 | 49 | 1.420 |
Why?
|
| Coronary Disease | 8 | 2015 | 56 | 1.320 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 45 | 1.290 |
Why?
|
| Secondary Prevention | 5 | 2020 | 45 | 1.290 |
Why?
|
| Cardiovascular Diseases | 5 | 2020 | 340 | 1.270 |
Why?
|
| Cardiology | 5 | 2021 | 52 | 1.260 |
Why?
|
| Coronary Artery Disease | 4 | 2017 | 126 | 0.960 |
Why?
|
| Cardiac Rehabilitation | 3 | 2020 | 7 | 0.930 |
Why?
|
| Exercise Test | 3 | 2018 | 103 | 0.770 |
Why?
|
| Heart Failure | 7 | 2021 | 166 | 0.770 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 228 | 0.700 |
Why?
|
| Acute Coronary Syndrome | 3 | 2016 | 14 | 0.690 |
Why?
|
| Humans | 39 | 2023 | 25692 | 0.680 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 8 | 0.680 |
Why?
|
| Acrylamides | 1 | 2019 | 2 | 0.670 |
Why?
|
| Aniline Compounds | 1 | 2019 | 31 | 0.660 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 14 | 0.660 |
Why?
|
| Medicine | 2 | 2008 | 10 | 0.630 |
Why?
|
| Physicians, Family | 2 | 2008 | 6 | 0.620 |
Why?
|
| Specialization | 2 | 2008 | 16 | 0.620 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2018 | 15 | 0.610 |
Why?
|
| Lipocalin-2 | 1 | 2018 | 2 | 0.610 |
Why?
|
| Cystatin C | 1 | 2018 | 3 | 0.610 |
Why?
|
| Life Style | 3 | 2019 | 172 | 0.600 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 509 | 0.600 |
Why?
|
| Mutation | 1 | 2019 | 325 | 0.590 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 169 | 0.580 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 36 | 0.580 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 222 | 0.580 |
Why?
|
| Hypertension | 2 | 2019 | 201 | 0.580 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2017 | 2 | 0.560 |
Why?
|
| Taxoids | 1 | 2017 | 10 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 284 | 0.550 |
Why?
|
| ErbB Receptors | 3 | 2023 | 52 | 0.530 |
Why?
|
| Cell Proliferation | 1 | 2017 | 167 | 0.530 |
Why?
|
| Apoptosis | 1 | 2017 | 177 | 0.520 |
Why?
|
| Neoplasms | 1 | 2018 | 224 | 0.490 |
Why?
|
| Coronary Artery Bypass | 1 | 2014 | 26 | 0.460 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 37 | 0.460 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 140 | 0.450 |
Why?
|
| Return to Work | 1 | 2014 | 53 | 0.450 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 26 | 0.440 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 39 | 0.430 |
Why?
|
| Aged | 18 | 2023 | 8501 | 0.420 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 369 | 0.420 |
Why?
|
| Middle Aged | 15 | 2019 | 8403 | 0.360 |
Why?
|
| Male | 17 | 2023 | 13917 | 0.360 |
Why?
|
| Risk Factors | 11 | 2019 | 2224 | 0.340 |
Why?
|
| Prognosis | 4 | 2021 | 739 | 0.340 |
Why?
|
| Chest Pain | 1 | 2009 | 18 | 0.330 |
Why?
|
| Program Evaluation | 2 | 2009 | 124 | 0.330 |
Why?
|
| Female | 16 | 2019 | 14273 | 0.320 |
Why?
|
| Models, Statistical | 1 | 2009 | 120 | 0.320 |
Why?
|
| Medication Adherence | 1 | 2009 | 72 | 0.310 |
Why?
|
| Biomarkers | 3 | 2020 | 554 | 0.300 |
Why?
|
| Australia | 7 | 2021 | 37 | 0.290 |
Why?
|
| Death, Sudden | 1 | 2006 | 6 | 0.270 |
Why?
|
| Risk Assessment | 5 | 2019 | 618 | 0.240 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 48 | 0.230 |
Why?
|
| Prevalence | 2 | 2019 | 435 | 0.220 |
Why?
|
| Depression | 2 | 2018 | 412 | 0.220 |
Why?
|
| Prospective Studies | 5 | 2018 | 1633 | 0.220 |
Why?
|
| Cetuximab | 1 | 2023 | 6 | 0.220 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 37 | 0.210 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 28 | 0.210 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 40 | 0.200 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 58 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 4459 | 0.190 |
Why?
|
| Radiosurgery | 1 | 2021 | 33 | 0.190 |
Why?
|
| DDT | 1 | 2020 | 1 | 0.180 |
Why?
|
| Insulin-Secreting Cells | 1 | 2020 | 11 | 0.180 |
Why?
|
| Comorbidity | 4 | 2021 | 457 | 0.170 |
Why?
|
| Adult | 7 | 2018 | 7336 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2020 | 138 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3220 | 0.170 |
Why?
|
| Proteomics | 1 | 2020 | 85 | 0.170 |
Why?
|
| United Kingdom | 1 | 2019 | 52 | 0.170 |
Why?
|
| Blood Circulation | 1 | 2019 | 1 | 0.170 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 2 | 0.170 |
Why?
|
| Young Adult | 3 | 2018 | 1855 | 0.170 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 4 | 0.170 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 53 | 0.170 |
Why?
|
| Walking Speed | 1 | 2019 | 40 | 0.160 |
Why?
|
| France | 1 | 2019 | 14 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 33 | 0.160 |
Why?
|
| Diastole | 1 | 2019 | 27 | 0.160 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 15 | 0.160 |
Why?
|
| Waist Circumference | 1 | 2019 | 35 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 36 | 0.160 |
Why?
|
| Stroke Volume | 1 | 2019 | 49 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 10 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 149 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 57 | 0.160 |
Why?
|
| American Heart Association | 1 | 2018 | 15 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2019 | 71 | 0.160 |
Why?
|
| Mouth | 1 | 2018 | 15 | 0.160 |
Why?
|
| Bias | 2 | 2008 | 37 | 0.150 |
Why?
|
| Pharynx | 1 | 2018 | 12 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 77 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 80 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2018 | 75 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 47 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 227 | 0.150 |
Why?
|
| Aspirin | 1 | 2018 | 74 | 0.150 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 129 | 0.140 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 4 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2019 | 410 | 0.140 |
Why?
|
| Caspases | 1 | 2017 | 25 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2017 | 33 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 195 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 110 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2019 | 1781 | 0.140 |
Why?
|
| Blotting, Western | 1 | 2017 | 140 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2019 | 419 | 0.140 |
Why?
|
| Smartphone | 1 | 2016 | 15 | 0.130 |
Why?
|
| United States | 3 | 2018 | 1943 | 0.130 |
Why?
|
| Telephone | 2 | 2014 | 25 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 847 | 0.130 |
Why?
|
| Quality of Life | 3 | 2016 | 600 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2016 | 85 | 0.130 |
Why?
|
| Patient Compliance | 3 | 2016 | 148 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 184 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3231 | 0.110 |
Why?
|
| Calcium | 1 | 2017 | 364 | 0.110 |
Why?
|
| Depressive Disorder | 2 | 2015 | 166 | 0.110 |
Why?
|
| Elective Surgical Procedures | 1 | 2013 | 38 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2013 | 116 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2013 | 60 | 0.100 |
Why?
|
| New Zealand | 3 | 2020 | 11 | 0.100 |
Why?
|
| Health Behavior | 2 | 2003 | 136 | 0.100 |
Why?
|
| Affect | 1 | 2011 | 58 | 0.090 |
Why?
|
| Family Practice | 1 | 2009 | 13 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2009 | 39 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 6 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 29 | 0.080 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 24 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 21 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 26 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 59 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2009 | 101 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 102 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 53 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 443 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2013 | 827 | 0.070 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 15 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2006 | 18 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 731 | 0.070 |
Why?
|
| Time Factors | 1 | 2009 | 1336 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 308 | 0.060 |
Why?
|
| Cholesterol | 2 | 2003 | 59 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1689 | 0.060 |
Why?
|
| Hypercholesterolemia | 2 | 2002 | 26 | 0.060 |
Why?
|
| Immobilization | 1 | 2023 | 12 | 0.060 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 9 | 0.060 |
Why?
|
| Counseling | 1 | 2003 | 41 | 0.060 |
Why?
|
| Laryngectomy | 1 | 2023 | 16 | 0.050 |
Why?
|
| Neck | 1 | 2023 | 23 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 36 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 58 | 0.050 |
Why?
|
| Victoria | 2 | 2019 | 8 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2003 | 51 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 65 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 32 | 0.050 |
Why?
|
| Cardiovascular Agents | 2 | 2013 | 27 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2002 | 12 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 4 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 300 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 198 | 0.050 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2020 | 9 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 38 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 110 | 0.040 |
Why?
|
| Health Promotion | 1 | 2002 | 140 | 0.040 |
Why?
|
| Cell Line | 1 | 2020 | 268 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 90 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 17 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 65 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 262 | 0.040 |
Why?
|
| Echocardiography | 1 | 2019 | 88 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 143 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 698 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 129 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 103 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 154 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 427 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 396 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 183 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 716 | 0.030 |
Why?
|
| Text Messaging | 1 | 2016 | 16 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2016 | 30 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 104 | 0.030 |
Why?
|
| Independent Living | 1 | 2018 | 294 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 913 | 0.030 |
Why?
|
| Anxiety | 1 | 2015 | 150 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 188 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2013 | 10 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 46 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2013 | 24 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2013 | 63 | 0.030 |
Why?
|
| Hypolipidemic Agents | 2 | 2003 | 25 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 37 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 53 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 207 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 21 | 0.020 |
Why?
|
| Aftercare | 1 | 2006 | 18 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 39 | 0.020 |
Why?
|
| Physical Examination | 1 | 2006 | 110 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 99 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2003 | 11 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2003 | 41 | 0.010 |
Why?
|
| Europe | 1 | 2002 | 64 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 126 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 256 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 299 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2002 | 170 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 177 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 290 | 0.010 |
Why?
|